Panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma

Authors :: Christine McCluskey
Andrew D. Norden
Tracy T. Batchelor
Patrick Y. Wen
Lakshmi Nayak
David Schiff
Rameen Beroukhim
Jan Drappatz
Sarah C. Gaffey
Kelly Hempfling
Andrew S. Chi
Sean Grimm
Jeffrey Raizer
Mikael L. Rinne
Katrina H. Smith
Eudocia Q. Lee
David A. Reardon
Alona Muzikansky
Brendan Wrigley
Source :: Journal of Clinical Oncology. 32:2020-2020
Publication Year :: 2014
Publisher :: American Society of Clinical Oncology (ASCO), 2014.
Abstract: 2020 Background: Bevacizumab is frequently used to treat recurrent high-grade gliomas, but responses are generally not durable. Panobinostat is a histone deacetylase inhibitor with anti-neoplastic ...

Subjects :: Cancer Research
Pathology
medicine.medical_specialty
Bevacizumab
medicine.drug_class
business.industry
Recurrent glioblastoma
Histone deacetylase inhibitor
Anaplastic glioma
chemistry.chemical_compound
Oncology
chemistry
Panobinostat
Cancer research
medicine
business
medicine.drug

Full Text Access

Tools